Good Sunday Morning! This is a week within which many critical decisions about the future of human civilization will depend. The US Election has obvious and huge ...

LESOTHO is being challenged to transform its HIV response for sustainability by 2030 and beyond, as declining funding and competing priorities threaten progress. This was said by the UNAIDS ...

Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking Therapeutics is a clinical-stage biotech that's looking to compete with Lilly in ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products that claimed to contain tirzepatide, the main ingredient in its popular weight-loss medicine ...

Eli Lilly's weight loss drug sales in Q3 weren't as strong as it anticipated. Its earnings will continue to grow at a rapid pace regardless. It still has a couple of levers it can pull to drive ...

MangoRx said it “strongly refutes” claims made by Eli Lilly that it improperly copied blockbuster weight-loss medicines for sale on its telemedicine platform. MangoRx was responding to Eli ...

Oct 21 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its ...

A group of U.S. senators is digging into the direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer this year in search of any indication the services could create conflicts of ...

With its 1-star rating, we believe Eli Lilly’s stock is significantly overvalued compared with our long-term fair value estimate of $580 per share. Our assumptions for overall biopharma GLP-1 ...

A turbulent series of events surrounding the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around how the Food and Drug Administration maintains its list of drug ...